As fo­cus shifts to on­col­o­gy, BioN­Tech nabs No­var­tis ex­ec as chief com­mer­cial of­fi­cer

BioN­Tech has hired one of No­var­tis’ ra­di­oli­gand ther­a­py lead­ers as its new chief com­mer­cial of­fi­cer, as the com­pa­ny looks to piv­ot from re­liance on its Covid fran­chise and be­come a mul­ti-prod­uct com­pa­ny.

Mean­while, the Ger­man drug­mak­er ter­mi­nat­ed an ear­ly-phase study that com­bines one of its can­cer vac­cines with Re­gen­eron’s Lib­tayo in prostate can­cer, as it tout­ed its wider on­col­o­gy pipeline on Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.